Total Payments
$971,182
2024 Payments
$133,865
Companies
32
Transactions
1,553
Medicare Patients
856
Medicare Billing
$154,549
Payment Breakdown by Category
Other$751,583 (77.4%)
Travel$123,984 (12.8%)
Consulting$64,439 (6.6%)
Food & Beverage$30,544 (3.1%)
Education$532.84 (0.1%)
Research$100.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $751,583 | 359 | 77.4% |
| Travel and Lodging | $123,984 | 531 | 12.8% |
| Consulting Fee | $64,439 | 21 | 6.6% |
| Food and Beverage | $30,544 | 630 | 3.1% |
| Education | $532.84 | 11 | 0.1% |
| Unspecified | $100.00 | 1 | 0.0% |
Payments by Type
General
$971,082
1,552 transactions
Research
$100.00
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Neurocrine Biosciences, Inc. | $622,853 | 816 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $53,739 | 102 | $0 (2022) |
| Alkermes, Inc. | $51,170 | 92 | $0 (2024) |
| PFIZER INC. | $38,173 | 68 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $37,392 | 61 | $0 (2024) |
| ABBVIE INC. | $32,263 | 65 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $24,946 | 55 | $0 (2017) |
| Avanir Pharmaceuticals, Inc. | $23,706 | 49 | $0 (2022) |
| Eisai Inc. | $19,717 | 39 | $0 (2021) |
| Teva Pharmaceuticals USA, Inc. | $18,297 | 45 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $133,865 | 204 | Neurocrine Biosciences, Inc. ($79,562) |
| 2023 | $139,293 | 184 | Neurocrine Biosciences, Inc. ($100,335) |
| 2022 | $104,624 | 122 | Neurocrine Biosciences, Inc. ($100,624) |
| 2021 | $101,428 | 137 | Neurocrine Biosciences, Inc. ($72,474) |
| 2020 | $43,442 | 83 | Neurocrine Biosciences, Inc. ($35,350) |
| 2019 | $135,797 | 274 | Neurocrine Biosciences, Inc. ($88,860) |
| 2018 | $205,973 | 356 | Neurocrine Biosciences, Inc. ($122,315) |
| 2017 | $106,761 | 193 | Merck Sharp & Dohme Corporation ($24,946) |
All Payment Transactions
1,553 individual payment records from CMS Open Payments — Page 1 of 63
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $60.30 | General |
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $44.91 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $33.50 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $26.88 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $24.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,140.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,656.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,380.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $59.30 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/10/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $513.60 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/10/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $418.95 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/10/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $86.92 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $144.10 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $60.30 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $56.92 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $46.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/03/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,416.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/03/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,840.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/03/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,380.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/25/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,840.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/25/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $435.07 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/25/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $401.15 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/25/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $153.46 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/22/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $21.31 | General |
| Category: Neuropsychiatry | ||||||
| 11/21/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,250.00 | General |
| Category: Neuropsychiatry | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ReKinect Study | Neurocrine Biosciences, Inc. | $100.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 223 | 576 | $72,377 | $38,286 |
| 2022 | 3 | 190 | 592 | $60,685 | $36,795 |
| 2021 | 2 | 199 | 651 | $65,100 | $41,225 |
| 2020 | 3 | 244 | 689 | $74,400 | $38,243 |
Total Patients
856
Total Services
2,508
Medicare Billing
$154,549
Procedure Codes
13
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 150 | 472 | $53,853 | $28,349 | 52.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 30 | 49 | $8,545 | $4,449 | 52.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 16 | 16 | $5,600 | $2,810 | 50.2% |
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Facility | 2023 | 12 | 17 | $2,179 | $1,436 | 65.9% |
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Facility | 2023 | 15 | 22 | $2,200 | $1,242 | 56.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 156 | 541 | $54,100 | $33,054 | 61.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 18 | 27 | $4,185 | $2,698 | 64.5% |
| 99308 | Follow-up nursing facility visit per day, typically 15 minutes | Facility | 2022 | 16 | 24 | $2,400 | $1,042 | 43.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 173 | 604 | $60,400 | $38,738 | 64.1% |
| 99308 | Subsequent nursing facility visit, typically 15 minutes per day | Facility | 2021 | 26 | 47 | $4,700 | $2,487 | 52.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 189 | 611 | $61,100 | $31,511 | 51.6% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 22 | 22 | $7,700 | $3,577 | 46.5% |
| 99308 | Subsequent nursing facility visit, typically 15 minutes per day | Facility | 2020 | 33 | 56 | $5,600 | $3,155 | 56.3% |
About Dr. John Hardy, MD
Dr. John Hardy, MD is a Forensic Psychiatry healthcare provider based in Pueblo, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1619032182.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Hardy, MD has received a total of $971,182 in payments from pharmaceutical and medical device companies, with $133,865 received in 2024. These payments were reported across 1,553 transactions from 32 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($751,583).
As a Medicare-enrolled provider, Hardy has provided services to 856 Medicare beneficiaries, totaling 2,508 services with total Medicare billing of $154,549. Data is available for 4 years (2020–2023), covering 13 distinct procedure/service records.
Ad
Practice Information
- Specialty Forensic Psychiatry
- Other Specialties Psychiatry, Child & Adolescent Psychiatry
- Location Pueblo, CO
- Active Since 12/26/2006
- Last Updated 01/11/2008
- Taxonomy Code 2084F0202X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1619032182
Products in Payments
- INGREZZA (Drug) $622,853
- LATUDA (Drug) $53,739
- VRAYLAR (Drug) $50,336
- CHANTIX (Drug) $38,173
- Aristada 441 mg (Drug) $30,765
- COBENFY (Drug) $27,053
- BELSOMRA (Drug) $24,946
- NUEDEXTA (Drug) $23,757
- Dayvigo (Drug) $19,717
- UZEDY (Drug) $17,638
- SPRAVATO (Drug) $15,971
- ARISTADA (Drug) $12,522
- Trintellix (Drug) $9,870
- CAPLYTA (Drug) $3,023
- REXULTI (Drug) $586.86
- LYBALVI (Drug) $479.66
- AUSTEDO (Drug) $265.14
- INVEGA (Drug) $237.18
- TRINTELLIX (Drug) $166.69
- NUPLAZID (Drug) $163.77
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.